Biosimilar drug authorization requirement change.

Biosimilar authorization change.

Effective for dates of service on or after November 1, 2026, the following pegfilgrastim biosimilars will require prior authorization for US Family Health Plan members:

• Q5108 – Fulphila^® (pegfilgrastim-jmdb)
• Q5130 – Fylnetra^® (pegfilgrastim-pbbk)
• Q5122 – Nyvepria^® (pegfilgrastim-apgf)
• Q5127 – Stimufend^® (pegfilgrastim-fpgk)
• Q5111 – Udenyca^® (pegfilgrastim-cbqv)
• Q5120 – Ziextenzo^® (pegfilgrastim-bmez)